目的 本文旨在评价国内真实世界中以帕妥珠单抗为基础的联合方案用于人表皮生长因子 受体 2（HER⁃2）阳性乳腺癌患者的新辅助治疗的疗效和安全性。方法 自 2019 年 3 月至 2022 年 1 月，于 广东省中医院乳腺科完成含帕妥珠单抗方案新辅助治疗及手术的 60 例 HER⁃2 阳性Ⅱ⁃Ⅲ乳腺癌患者，采 用 MRI 或 CT 及 Miler⁃Payne 标准行临床疗效评价与手术后病理评价。分析含帕妥珠单抗的新辅助方案在 HER⁃2 阳性乳腺癌患者中的疗效和不良反应。结果 60 例患者中，临床总缓解率（ORR）为 82%，病理有 效率（G3+G4+G5）为 90%，病理完全缓解率（pCR/G5）为 53%（32/60），其中表柔比星（E）联合环磷酰胺（C） 序贯多西他赛（T）化疗方案组 pCR 率最高，为 56%（18/32）。所有患者均未出现影响治疗的严重不良反应。 结论 在真实世界中，应用含帕妥珠单抗方案新辅助治疗 HER⁃2 阳性乳腺癌患者疗效确切，联合含蒽环 类化疗有更好获益可能，且安全性良好。 

Objective Pertuzumab（P）has been recommended as the first choice of neoadjuvant treat⁃ ment for the patients with human epidermal growth factor receptor 2（HER⁃2）positive breast cancer. There are few reports on real⁃world data in China nowadays. This study aims at investigating the clinical effects of the combination therapy based on pertuzumab in patients with HER⁃2 positive breast cancer. Methods From March 2019 to January 2022，there were 60 patients with HER⁃2 positive breast cancer who received neoadjuvant treatment with pertuzumab and underwent surgery from the Guangdong Hospital of Traditional Chinese Medicine. During the neoadjuvant treatment，We evaluated the clinical effects and postoperative pathology by magnetic resonance imaging orcomputed tomography andthe Miler⁃Payne standard. Which we used to analyze the clinical effects and adverse reaction of the combination therapy based on pertuzumab in HER⁃2 positive breast cancer patients. Results Of the 60 patients who were enrolled，the overall response rete（ORR）was 82%，the pathological effective rate（G3 + G4 + G5）was 90%，and the pathological complete response rate（pCR/G5）was 53%（32/60）. Epirubicin（e）combined with cyclophosphamide（c）sequential docetaxel（T）chemotherapy group hasthe highest pCR rate，56%（18/32）. No serious event was observed during the treatment. Conclusion In the real world，the neoadjuvant therapy combined⁃ with pertuzumab for HER⁃2 positive breast cancer patientsis safe and effective，especially combined anthracycline containing chemotherapy.